Glycemic Monitoring in Cystic Fibrosis

Inclusion criteria

Healthy controls (n=45) -

• Age 10-25 years
• BMI <85th percentile
• Baseline health at enrollment

CF controls (n=45) -

• Age 10-25 years
• Diagnosis of cystic fibrosis (by newborn screen, sweat chloride testing, or genetic testing)
• Baseline health at enrollment (no inclusion/exclusion criteria for CF patients based on lung function, BMI, pancreatic insufficiency, or genotype)

CF prediabetes & CFRD (n=70)

• Age 10-25 years
• Diagnosis of cystic fibrosis (by newborn screen, sweat chloride testing, or genetic testing)
• History of abnormal oral glucose tolerance testing (2h-glucose >140, fasting plasma glucose >100,1hr glucose >200)
• If taking medication that affects glucose metabolism (ex. Insulin, insulin sensitizers, glucocorticoids, atypical antipsychotics), should be on a stable dose over the past 3 months

Exclusion criteria

Healthy controls -

• Known diagnosis of diabetes or prediabetes (including type 1, type 2, MODY), abnormal oral glucose tolerance test (OGTT) (ie. fasting plasma glucose ≥100 or 2hr ≥140 mg/dl) or HbA1c ≥ 5.7%
• BMI ≥85th percentile
• Chronic disease that may affect glucose metabolism or use of medications affecting glucose metabolism in the past 3 months (ex. Insulin, insulin sensitizers, glucocorticoids, atypical antipsychotics)
• Presence of type 1 diabetes auto-antibodies in any individuals with a first degree relative with type 1 diabetes (will only include first degree relatives if they have had previous negative auto-antibody screening performed as part of participation in other studies such as the Trial Net studies at the Barbara Davis Center)
• Acute illness (ex. Asthma exacerbation, gastroenteritis, febrile illness)
• Pregnancy

CF participants -

• Diagnosis of type 1 diabetes, type 2 diabetes, or MODY
• Varying doses of medication affecting glucose metabolism in the past 3 months
• Pulmonary exacerbation associated with hospitalization, or systemic steroid requirement in the preceding 6 weeks
• Pregnancy